N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Melanoma, Radiotherapy, Metastatic Disease
Both
Melanoma, Radiotherapy, Metastatic Disease
Trial Information
Serum is taken from each melanoma patient at every follow up after signed concent. With
ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for
metastasis by oncologists.
Inclusion Criteria:
- uveal melanoma (With/without overt metastatic disease)
Type of Study:
Observational
Study Design:
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal, Time Perspective: Prospective
Principal Investigator
Ulrich C Schaller, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Munich, Germany
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
MIA
NCT ID:
NCT00406900
Start Date:
January 1999
Completion Date:
September 2006
Related Keywords:
- Melanoma
- Radiotherapy
- Metastatic Disease
- uveal melanoma
- metastatic disease
- Melanoma
- Neoplasm Metastasis
Name | Location |
|---|
